Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
14 10 2021
Historique:
received: 09 06 2021
revised: 25 06 2021
accepted: 06 08 2021
pubmed: 19 8 2021
medline: 21 10 2021
entrez: 18 8 2021
Statut: ppublish

Résumé

We recently reported five cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) 7-10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against corona virus disease 2019 (COVID-19). We aimed to investigate the pathogenic immunological responses operating in these patients. We assessed circulating inflammatory markers by immune assays and immune cell phenotyping by flow cytometry analyses and performed immunoprecipitation with anti-platelet factor (PF)4 antibody in plasma samples followed by mass spectrometry from all five patients. A thrombus was retrieved from the sinus sagittal superior of one patient and analysed by immunohistochemistry and flow cytometry. Precipitated immune complexes revealed multiple innate immune pathway triggers for platelet and leucocyte activation. Plasma contained increased levels of innate immune response cytokines and markers of systemic inflammation, extensive degranulation of neutrophils, and tissue and endothelial damage. Blood analyses showed activation of neutrophils and increased levels of circulating H3Cit, dsDNA, and myeloperoxidase-DNA complex. The thrombus had extensive infiltration of neutrophils, formation of neutrophil extracellular traps (NETs), and IgG deposits. The results show that anti-PF4/polyanion IgG-mediated thrombus formation in VITT patients is accompanied by a massive innate immune activation and particularly the fulminant activation of neutrophils including NETosis. These results provide novel data on the immune response in this rare adenoviral vector-induced VITT.

Identifiants

pubmed: 34405870
pii: 6354117
doi: 10.1093/eurheartj/ehab506
pmc: PMC8385969
doi:

Substances chimiques

Antigen-Antibody Complex 0
COVID-19 Vaccines 0
Vaccines 0
ChAdOx1 nCoV-19 B5S3K2V0G8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4064-4072

Subventions

Organisme : South-Eastern Norway Regional Health Authority
ID : 2021071
Organisme : Core Facilities program
Organisme : National network of Advanced Proteomics Infrastructure (NAPI)-the Research Council of Norway (RCN)
ID : 295910
Organisme : RCN Covid
ID : 312693
Organisme : KG Jebsen Foundation
ID : 19
Organisme : Coalition for Epidemic Preparedness Innovations (CEPI); and the University of Oslo and Oslo University Hospital
Organisme : South-Eastern Norway Regional Health Authority
Organisme : National network of Advanced Proteomics Infrastructure
Organisme : Research Council of Norway
ID : 295910
Organisme : University of Oslo
Organisme : Oslo University Hospital

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Sverre Holm (S)

Research Institute of Internal Medicine, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.

Hassen Kared (H)

KG Jebsen Centre for B Cell Malignancies, University of Oslo, Postbox 4950, 0424 Oslo, Norway.
Department of Immunology, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.

Annika E Michelsen (AE)

Research Institute of Internal Medicine, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.

Xiang Yi Kong (XY)

Research Institute of Internal Medicine, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.

Tuva B Dahl (TB)

Research Institute of Internal Medicine, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.
Division of Emergencies and Critical Care, Department of Research and Development, Oslo University Hospital, Postbox 4950, N-0424 Oslo, Norway.

Nina H Schultz (NH)

Department of Haematology, Oslo University Hospital, Postbox 4950, N-0424 Oslo, Norway.
Department of Haematology, Akershus University Hospital, Postbox 1000, 1478 Lørenskog, Norway.

Tuula A Nyman (TA)

Department of Immunology, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.

Cathrine Fladeby (C)

Department of Microbiology, Oslo University Hospital, Postbox 4950, N-0424 Oslo, Norway.

Ingebjørg Seljeflot (I)

Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.
Department of Cardiology, Oslo University Hospital, Postbox 4950, N-0424 Oslo, Norway.

Thor Ueland (T)

Research Institute of Internal Medicine, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.
Faculty of Health Sciences, K.G. Jebsen TREC, University of Tromsø, Postbox 6050, Langnes 9037 Tromsø, Norway.

Maria Stensland (M)

Department of Immunology, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.

Siri Mjaaland (S)

Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Postbox 222, Skøyen, 0213 Oslo, Norway.

Guro Løvik Goll (GL)

Division of Rheumatology and Research, Diakonhjemmet Hospital, Postbox 23 Vindern, 0319 Oslo, Norway.

Lise Sofie Nissen-Meyer (LS)

Department of Immunology, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.

Pål Aukrust (P)

Research Institute of Internal Medicine, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Postbox 4950, N-0424 Oslo, Norway.

Karolina Skagen (K)

Department of Neurology, Oslo University Hospital, Postbox 4950, N-0424 Oslo, Norway.

Ida Gregersen (I)

Research Institute of Internal Medicine, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.

Mona Skjelland (M)

Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.
Department of Neurology, Oslo University Hospital, Postbox 4950, N-0424 Oslo, Norway.

Pål A Holme (PA)

Research Institute of Internal Medicine, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.
Department of Haematology, Oslo University Hospital, Postbox 4950, N-0424 Oslo, Norway.

Ludvig A Munthe (LA)

KG Jebsen Centre for B Cell Malignancies, University of Oslo, Postbox 4950, 0424 Oslo, Norway.
Department of Immunology, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.

Bente Halvorsen (B)

Research Institute of Internal Medicine, Oslo University Hospital, Postbox 4950, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Postbox 1171, Blindern 0318 Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH